Literature DB >> 16490490

Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.

Jian-Ping Tong1, Wai-Man Chan, David T L Liu, Timothy Y Y Lai, Kwong-Wai Choy, Chi-Pui Pang, Dennis S C Lam.   

Abstract

PURPOSE: To determine the aqueous levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF) in patients with active polypoidal choroidal vasculopathy (PCV) and choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and pathologic myopia.
DESIGN: Prospective, comparative control study.
METHODS: Aqueous humors were collected from 32 eyes of 32 patients for either active PCV or CNV. Among them, 11 eyes had active and symptomatic PCV, 12 eyes had active CNV secondary to AMD, and nine eyes had active CNV of pathologic myopia. Levels of VEGF and PEDF were determined by commercially available enzyme-linked immunosorbent assay kits. A group of 10 aqueous samples from 10 patients who underwent cataract surgery without other ocular or systemic diseases comprised the controls.
RESULTS: VEGF concentrations in aqueous humor were markedly increased in patients with PCV, CNV of AMD, and CNV of myopia when compared with the controls (analysis of variance [ANOVA], P < .001). VEGF levels in eyes with PCV were, however, significantly lower than those of exudative AMD (P = .045). The PEDF levels were also significantly different among the groups (ANOVA, P = .001), and we observed increased levels in PCV, CNV of AMD, and CNV of myopia.
CONCLUSIONS: VEGF and PEDF factors were coexpressed and increased with positive correlation in aqueous humor of eyes with active PCV. The different levels of both factors in eyes of PCV and AMD might suggest distinct clinical entities or different angiogenesis courses between PCV and AMD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490490     DOI: 10.1016/j.ajo.2005.10.012

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  89 in total

1.  The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization.

Authors:  Tsung-Tien Wu; Ya-Hsin Kung
Journal:  J Ocul Pharmacol Ther       Date:  2011-11-08       Impact factor: 2.671

2.  Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab.

Authors:  Akitaka Tsujikawa; Sotaro Ooto; Kenji Yamashiro; Hiroshi Tamura; Atsushi Otani; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2010-08-11       Impact factor: 2.447

3.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

4.  Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.

Authors:  Masaaki Saito; Mariko Kano; Kanako Itagaki; Shigeyuki Ise; Kimihiro Imaizumi; Tetsuju Sekiryu
Journal:  Jpn J Ophthalmol       Date:  2015-09-09       Impact factor: 2.447

5.  Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

Authors:  Javier A Montero; Jose M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

6.  Dietary blueberry supplementation affects growth but not vascularization of neural transplants.

Authors:  Lauren M Willis; Brent J Small; Paula C Bickford; Claudia D Umphlet; Alfred B Moore; Ann-Charlotte E Granholm
Journal:  J Cereb Blood Flow Metab       Date:  2008-02-20       Impact factor: 6.200

7.  Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Chengguo Zuo; Feng Wen; Jiaqing Li; Yan Liu; Meng Li
Journal:  Doc Ophthalmol       Date:  2009-01-31       Impact factor: 2.379

8.  Effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in Korea.

Authors:  Young Gun Park; Seungbum Kang; Young Jung Roh
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

9.  Factors influencing visual outcome of polypoidal choroidal vasculopathy one year after photodynamic therapy.

Authors:  Ryusaburo Mori; Mitsuko Yuzawa; Zeon Lee; Miho Haruyama; Eriko Akaza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-30       Impact factor: 3.117

10.  Combined therapy versus anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy: a Meta-analysis.

Authors:  Long-Hui Han; Li-Fei Yuan; Xu Liang; Xin Jia; Ming-Lian Zhang
Journal:  Int J Ophthalmol       Date:  2017-08-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.